Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Earnings & Valuation
This table compares Lyell Immunopharma and HCW Biologics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 5,037.81 | -$274.45 million | ($12.83) | -0.64 |
| HCW Biologics | $50,000.00 | 54.88 | -$7.96 million | ($27.60) | -0.04 |
Profitability
This table compares Lyell Immunopharma and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
Institutional & Insider Ownership
66.0% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Lyell Immunopharma and HCW Biologics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
Lyell Immunopharma presently has a consensus price target of $40.86, indicating a potential upside of 396.74%. HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 2,348.98%. Given HCW Biologics’ higher probable upside, analysts plainly believe HCW Biologics is more favorable than Lyell Immunopharma.
Risk and Volatility
Lyell Immunopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.
Summary
HCW Biologics beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
